Tobi Nagel resumes & CV records
Resumes
Senior Scientist At Novartis Institutes For Biomedical Research
Location:
San Francisco Bay Area
Industry:
Biotechnology
Tobi Elaine Nagel, Age 58383 62Nd St, Oakland, CA 94618
Tobi Nagel Phones & Addresses
Oakland, CA
Sunnyvale, CA
395 Bellerose Dr, San Jose, CA 95128 (408) 885-0292
Redwood City, CA
999 Hamilton Ave, Campbell, CA 95008 (408) 378-3742
Burlingame, CA
South San Francisco, CA
Cambridge, MA
Menlo Park, CA
Social networks
Tobi Elaine Nagel
Linkedin
Industries
Biotechnology
Mentions for Tobi Elaine Nagel
Publications & IP owners
Us Patents
Combination Of (A) A Phosphoinositide 3-Kinase Inhibitor And (B) A Modulator Of Ras/Raf/Mek Pathway
US Patent:
2014005, Feb 27, 2014
Filed:
Oct 30, 2013
Appl. No.:
14/066734
Inventors:
Carlos Garcia-Echeverria - Saint-Cloud, FR
Sauveur-Michel Maira - Habsheim, FR
Darrin Stuart - Pleasant Hill CA, US
Susan Wee - Skillman NJ, US
Christine Fritsch - Steinbach, FR
Tobi Nagel - Oakland CA, US
Sauveur-Michel Maira - Habsheim, FR
Darrin Stuart - Pleasant Hill CA, US
Susan Wee - Skillman NJ, US
Christine Fritsch - Steinbach, FR
Tobi Nagel - Oakland CA, US
International Classification:
A61K 31/5377
A61K 45/06
A61K 31/437
A61K 31/166
A61K 31/4439
A61K 45/06
A61K 31/437
A61K 31/166
A61K 31/4439
US Classification:
5142322
Abstract:
The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which modulates the Ras/Raf/Mek pathway for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.
Combination Of (A) A Phosphoinositide 3-Kinase Inhibitor And (B) A Modulator Of Ras/Raf/Mek Pathway
US Patent:
2011010, May 5, 2011
Filed:
Jul 10, 2009
Appl. No.:
13/003581
Inventors:
Carlos Garcia-Echeverria - Basel, CH
Sauveur-Michel Maira - Habsheim, FR
Darrin Stuart - Pleasant Hill CA, US
Susan Wee - Skillman NJ, US
Christine Fritsch - Ranspach-le-bas, FR
Tobi Nagel - Oakland CA, US
Sauveur-Michel Maira - Habsheim, FR
Darrin Stuart - Pleasant Hill CA, US
Susan Wee - Skillman NJ, US
Christine Fritsch - Ranspach-le-bas, FR
Tobi Nagel - Oakland CA, US
Assignee:
NOVARTIS AG - Basel
International Classification:
A61K 31/496
A61K 31/4745
A61P 35/00
A61P 35/02
A61K 31/4745
A61P 35/00
A61P 35/02
US Classification:
51425303, 514293
Abstract:
The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which modulates the Ras/Raf/Mek pathway for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.
Combination Of (A) A Phosphoinositide 3-Kinase Inhibitor And (B) A Modulator Of Ras/Raf/Mek Pathway
US Patent:
2015010, Apr 16, 2015
Filed:
Dec 19, 2014
Appl. No.:
14/576314
Inventors:
Carlos Garcia-Echeverria - Saint-Cloud, FR
Sauveur-Michel Maira - Habsheim, FR
Darrin Stuart - Pleasant Hill CA, US
Susan Wee - Skillman NJ, US
Christine Fritsch - Steinbach, FR
Tobi Nagel - Oakland CA, US
Sauveur-Michel Maira - Habsheim, FR
Darrin Stuart - Pleasant Hill CA, US
Susan Wee - Skillman NJ, US
Christine Fritsch - Steinbach, FR
Tobi Nagel - Oakland CA, US
International Classification:
A61K 31/4745
A61K 31/166
A61K 31/166
US Classification:
514293
Abstract:
The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which modulates the Ras/Raf/Mek pathway for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.
NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.